The Gel Clot LAL Assay is the classical compendial method for the Bacterial Endotoxin Test (BET) and remains the qualitative reference standard described in USP <85>. Based on the coagulation reaction between horseshoe crab amebocyte lysate and bacterial endotoxins, this method provides a reliable and straightforward approach for detecting endotoxin contamination in pharmaceutical products, medical devices, and purified water.

The assay employs a highly sensitive LAL Reagent containing endotoxin-specific enzymes. When endotoxin is present, a proteolytic cascade is activated, resulting in the formation of a firm gel clot. The presence or absence of this clot determines the test outcome, making the method ideal for Qualitative Endotoxin Analysis without requiring complex instrumentation.

Compared with quantitative kinetic methods, the Gel Clot BET offers several practical advantages, including simple operation, low equipment requirements, excellent robustness, and cost-effective routine testing. It is particularly suitable for laboratories performing product release testing, process validation, raw material screening, and quality control under pharmacopeial guidelines.

Successful LAL Test performance depends on validated test conditions, appropriate endotoxin controls, and endotoxin-free accessories, including reagent water, glassware, and consumables. Positive Product Controls (PPC) and inhibition/enhancement studies are essential to verify that the sample matrix does not interfere with the lysate reaction, as required by USP <85>.

Although recombinant and quantitative endotoxin detection technologies continue to evolve, the LAL Assay based on the gel clot principle remains widely accepted because of its proven reliability, regulatory acceptance, and ease of implementation. For manufacturers seeking a dependable method for routine Bacterial Endotoxin Test, the Gel Clot LAL Assay continues to provide accurate, reproducible, and compliant results while meeting global pharmacopeial requirements.